Recent Developments in the Role of Coenzyme Q10 for Coronary Heart Disease: a Systematic Review
Purpose of Review
This review examines recent randomized clinical trials evaluating the role of coenzyme Q10 (CoQ10) in the management of coronary heart disease.
CoQ10 is one of the most commonly used dietary supplements in the USA. Due to its antioxidant and anti-inflammatory effects, CoQ10 has been studied extensively for possible use in managing coronary heart disease. One of the most common applications of CoQ10 is to mitigate statin-associated muscle symptoms (SAMS) based on the theory that SAMS are caused by statin depletion of CoQ10 in the muscle. Although previous studies of CoQ10 for SAMS have produced mixed results, CoQ10 appears to be safe. Because CoQ10 is a cofactor in the generation of adenosine triphosphate, supplementation has also recently been studied in patients with heart failure, which is inherently an energy deprived state. The Q-SYMBIO trial found that CoQ10 supplementation in patients with heart failure not only improved functional capacity, but also significantly reduced cardiovascular events and mortality. Despite these positive findings, a larger prospective trial is warranted to support routine use of CoQ10. Less impressive are the effects of CoQ10 on specific cardiovascular risk factors such as blood pressure, dyslipidemia, and glycemic control.
Current evidence does not support routine use of CoQ10 in patients with coronary heart disease. Additional studies are warranted to fully determine the benefit of CoQ10 in patients with heart failure before including it in guideline-directed medical therapy.
KeywordsCoenzyme Q10 Cardiovascular disease Heart failure Statins Myalgia
Compliance with Ethical Standards
Conflict of Interest
Jessica Ayers, Jamie Cook, Rachel A. Koenig, Evan M. Sisson, and Dave L. Dixon declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.• Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. National health statistics reports; no 79. Hyattsville, MD: National Center for Health Statistics. 2015. Discusses increase in use of co-enzyme Q10 over time. Google Scholar
- 2.Benjamin EJ, Virani SS, Callaway CW, Chang AR, Cheng C, Chiuve SE, et al. Heart Disease and Stroke Statistics—2018 update: a report from the American Heart Association. Circulation 2018;137; https://doi.org/10.1161/CIR.0000000000000558
- 7.Aljawad FH, Hashim HM, Jasim GA, Kadhim HM, Gorgi AQ, Jawad RF. Effects of atorvastatin and coenzyme Q10 on glycemic control and lipid profile in type 2 diabetic patients. Int J Pharm Sci Rev Res. 2015;34(2):183–6.Google Scholar
- 8.Mohseni M, Vafa MR, Hajimiresmail SJ, Zarrati M, Rahimi Forushani A, Bitarafan V, et al. Effects of coenzyme q10 supplementation on serum lipoproteins, plasma fibrinogen, and blood pressure in patients with hyperlipidemia and myocardial infarction. Iran Red Crescent Med J. 2014;16(10):e16433. https://doi.org/10.5812/ircmj.16433.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM, Nicholls MG, et al. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. Am J Hypertens. 2012;25(2):261–70. https://doi.org/10.1038/ajh.2011.209.CrossRefPubMedGoogle Scholar
- 10.Zahedi H, Eghtesadi S, Seifirad S, Rezaee N, Shidfar F, Heydari I, et al. Effects of CoQ10 supplementation on lipid profiles and glycemic control in patients with type 2 diabetes: a randomized, double blind, placebo-controlled trial. J Diabetes Metab Disord. 2014;13:81. https://doi.org/10.1186/s40200-014-0081-6.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.•• Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641–9. https://doi.org/10.1016/j.jchf.2014.06.008. First randomized double-blind trial demonstrating co-enzyme Q10 may reduce morbidity and mortality in patients with heart failure. CrossRefPubMedGoogle Scholar
- 13.Buettner C, Davis RB, Phillips RS, Mittleman MA. CoQ10 does not improve statin myalgia—a randomized controlled trial [abstract]. Atherosclerosis. 2015;e206:241.Google Scholar
- 14.Mazirka P, Jones E, Strachan P, McNurlan M, Lawson W, Caso G. Effect of coenzyme Q10 supplementation in patients with statin-related myalgia [abstract]. FASEB J. 2015;29(1_supplement):LB334.Google Scholar
- 15.Taylor BA, Lorson L, White M, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238(2):329–35. https://doi.org/10.1016/j.atherosclerosis.2014.12.016.CrossRefPubMedGoogle Scholar
- 17.•• Banach Maciej SC, Sahebkar A, Ursoniu S, Rysz J, Muntner P, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):23–34. https://doi.org/10.1016/j.mayocp.2014.08.021. Meta-analysis of previously conducted randomized clinical trials evaluating use of co-enzyme Q10 for statin-induced myopathy. Google Scholar
- 26.Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. https://doi.org/10.1016/j.jacc.2013.05.019.CrossRefPubMedGoogle Scholar
- 32.Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta. 1992;1126(3):247–54.CrossRefPubMedGoogle Scholar